PA (IMMUNOPRECISE ANTIBODIES LTD.) ( “IPA”) (NASDAQ: IPA), an advanced biotherapeutic research and technology company, today announced that BioStrand BV (“BioStrand”), an AI in silico discovery subsidiary of IPA, has entered into a research collaboration and license agreement (the “Agreement”) with BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT) (“BriaCell”), a clinical-stage biotechnology company specializing …
Bria-IMT™ regimen in combination with Incyte’s retifanlimab produced evidence of disease control, tumor shrinkage, and potential survival benefit amongst BriaCell’s recent 12 patient cohort in advanced breast cancer. The regimen remains well tolerated as recently reported in Phase I evaluation. 70% of patients showed either disease control or progression-free survival (PFS) benefits compared with their …
BriaCell has successfully completed its Phase I safety and tolerability evaluation of Bria-IMT™ in combination with Incyte’s retifanlimab in advanced breast cancer. The combination treatment showed a favorable safety profile in 12 patients. Phase II efficacy portion of the study, under FDA’s fast track designation, now underway with survival data and clinical benefit being compiled. …
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 12, 2022 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, announces today that it has added Mayo Clinic, Jacksonville, Florida as a clinical site in the Phase I/II study of BriaCell’s …
PHILADELPHIA and VANCOUVER, British Columbia, Sept. 28, 2022 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, is pleased to announce that its lead product candidate, Bria-IMT™, will be featured in three posters during the 2022 San Antonio …
PHILADELPHIA and VANCOUVER, British Columbia, Sept. 14, 2022 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, announces that it has signed an agreement with Caris Life Sciences ® (Caris), a leading molecular science and technology company actively …
PHILADELPHIA and VANCOUVER, British Columbia, Sept. 07, 2022 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, announces a poster presentation at the Society for Immunotherapy of Cancer (SITC) 37 th Annual Meeting, held November 10-12, 2022, in …
PHILADELPHIA and VANCOUVER, British Columbia, Aug. 04, 2022 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, announces that it has secured an exclusive license from University of Maryland, Baltimore County (UMBC) to develop and commercialize Soluble CD80 …
Extended survival and tumor shrinkage in advanced breast cancer patients who matched the immunotherapy HLA types, lead to the development of BriaCell’s prostate cancer program based on the patient’s HLA type. Bria-Pros™ is a novel off-the-shelf personalized immunotherapy approach to treating prostate cancer. Waisman Biomanufacturing has entered an agreement with BriaCell to manufacture clinical supplies …
PHILADELPHIA and VANCOUVER, British Columbia, June 29, 2022 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, today announced a research collaboration agreement with Harvard Medical School in support of a project led by Joan S. Brugge, PhD, …